Select committee: Health and Social Care Committee
Recommendation 7
Tenth Report - Prevention in health and social care: vaccination
Published 27 Jul 2023
Paragraph 28
Addressed to Department of Health and Social Care
Health and Social Care Committee Prevention in health and social care All items in this report Report on parliament.uk ↗ Inquiry on parliament.uk ↗
Recommendation (the committee's words)
The NHS England integrated vaccination and immunisation strategy must: a) have a strong focus on the action that is needed to tackle the practical challenges that limit access to vaccination; b) set out how to make best use of the wide range of healthcare professionals able to administer vaccinations; c) empower local leaders to pursue ways of addressing uptake in their own areas; and d) set out guidance and examples of best practice around how voices other than NHS England can be used to communicate important messaging about vaccination programmes.
From: Health and Social Care Committee, Tenth Report - Prevention in health and social care: vaccination (HC 1764), paragraph 28, 27 July 2023
Government response
The government responded to the whole report on 20 October 2023 (deadline 27 September 2023).
Summary written by Accountability Index from the government's response. It is not the government's own words.The Government responds to each of the Committee's five recommendations, setting out ongoing work and consultations, and states it is committed to improving vaccination uptake and regaining the UK's position as a global leader in clinical trials.
- On widening the vaccination workforce, the Government says it is "reviewing" the use of unregistered professionals, and a consultation launched on 7 August 2023 (closed 18 September 2023) includes an option for a time limited amendment, covering until April 2026, to regulation 247A.
- On NHS England's vaccination and immunisation delivery strategy, it says "latest thinking" focuses on empowering system leaders to plan local services, and that "the strategy will be published later in 2023".
- On the O'Shaughnessy review of commercial clinical trials, it has welcomed all recommendations "in principle" and "will consider" delivery of all of them, with "an implementation update" to be provided "in the autumn".
- On the JCVI and MHRA, it describes the UK system for reviewing new immunisation products as "effective and responsive" and notes £10 million over two years announced for the MHRA at Spring Budget.